A participant died in a clinical trial of a Federal Drug Administration-approved antibody treatment for Alzheimer’s disease, and the death may be linked to the drug, a new case report reveals. The case, published in May in the Journal of Alzheimer’s Disease, details unreported adverse outcomes associated with the use of Lecanemab (Lequembi), an anti-amyloid…
Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval
A group of independent advisers to the U.S. Food and Drug Administration (FDA) have voted to support regulatory approval of the Alzheimer’s drug Leqembi, also known by its generic name lecanemab, despite concerns surrounding three deaths during clinical trials. The six members on the Peripheral and Central Nervous System Drugs Advisory Committee on Friday all voted…
Lecanemab May Reverse Alzheimer’s Disease But 3 Deaths Raise Questions
The U.S. Food and Drug Administration (FDA) granted Leqembi accelerated approval on Jan. 6, 2023. It is the seventh drug the FDA has approved for the treatment of Alzheimer’s disease. The generic name of the drug is Lecanemab. It has been developed by the Japanese company Eisai in partnership with the U.S. company Biogen. These are…
FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab
The U.S. Food and Drug Administration (FDA) on Friday granted accelerated approval for the experimental dementia drug lecanemab. Lecanemab, which will be marketed as Leqembi, is the second of a new class of Alzheimer’s disease drugs that target the illness’s core pathophysiology, according to the FDA, which said the drug is a significant step forward…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`